dc.creator | CORTEZ, Afonso José Pereira | |
dc.creator | DULLEY, Frederico Luiz | |
dc.creator | SABOYA, Rosaura | |
dc.creator | MENDRONE JÚNIOR, Alfredo | |
dc.creator | AMIGO FILHO, Ulisses | |
dc.creator | CORACIN, Fabio Luiz | |
dc.creator | BUCCHERI, Valéria | |
dc.creator | LINARDI, Camila da Cruz Gouveia | |
dc.creator | RUIZ, Milton Artur | |
dc.creator | CHAMONE, Dalton de Alencar Fischer | |
dc.date.accessioned | 2012-03-26T18:23:46Z | |
dc.date.accessioned | 2018-07-04T14:11:15Z | |
dc.date.available | 2012-03-26T18:23:46Z | |
dc.date.available | 2018-07-04T14:11:15Z | |
dc.date.created | 2012-03-26T18:23:46Z | |
dc.date.issued | 2011 | |
dc.identifier | Revista Brasileira de Hematologia e Hemoterapia, v.33, n.1, p.10-14, 2011 | |
dc.identifier | 1516-8484 | |
dc.identifier | http://producao.usp.br/handle/BDPI/8927 | |
dc.identifier | 10.5581/1516-8484.20110007 | |
dc.identifier | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000100007 | |
dc.identifier | http://www.scielo.br/pdf/rbhh/v33n1/v33n1a07.pdf | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1606935 | |
dc.description.abstract | BACKGROUND: Hodgkin's lymphoma has high rates of cure, but in 15% to 20% of general patients and between 35% and 40% of those in advanced stages, the disease will progress or will relapse after initial treatment. For this group, hematopoietic stem cell transplantation is considered one option of salvage therapy. OBJECTIVES: To evaluate a group of 106 patients with Hodgkin's lymphoma, who suffered relapse or who were refractory to treatment, submitted to autologous hematopoietic stem cell transplantation in a single transplant center. METHODS: A retrospective study was performed with data collected from patient charts. The analysis involved 106 classical Hodgkin's lymphoma patients who were consecutively submitted to high-dose chemotherapy followed by autologous transplants in a single institution from April 1993 to December 2006. RESULTS: The overall survival rates of this population at five and ten years were 86% and 70%, respectively. The disease-free survival was approximately 60% at five years. Four patients died of procedure-related causes but relapse of classical Hodgkin's lymphoma after transplant was the most frequent cause of death. Univariate analysis shows that sensitivity to pre-transplant treatment and hemoglobin < 10 g/dL at diagnosis had an impact on patient survival. Unlike other studies, B-type symptoms did not seem to affect overall survival. Lactic dehydrogenase and serum albumin concentrations analyzed at diagnosis did not influence patient survival either. CONCLUSION: Autologous hematopoietic stem cell transplantation is an effective treatment strategy for early and late relapse in classical Hodgkin's lymphoma for cases that were responsive to pre-transplant chemotherapy. Refractory to treatment is a sign of worse prognosis. Additionally, a hemoglobin concentration below 10 g/dL at diagnosis of Hodgkin's lymphoma has a negative impact on the survival of patients after transplant. As far as we know this relationship has not been previously reported. | |
dc.language | eng | |
dc.publisher | Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea | |
dc.relation | Revista Brasileira de Hematologia e Hemoterapia | |
dc.rights | Copyright Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea | |
dc.rights | openAccess | |
dc.subject | Hodgkin's lymphoma | |
dc.subject | Hematopoietic stem cell transplantation | |
dc.subject | Autologous transplantation | |
dc.subject | Doxorubicin | |
dc.subject | Bleomycynm | |
dc.subject | Vinblastine | |
dc.subject | Dacarbazine | |
dc.subject | Study retrospective | |
dc.title | Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma | |
dc.type | Artículos de revistas | |